Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 6 Mar 2025 |
| Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons | 4 Mar 2025 |
| Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab | 28 Feb 2025 |
| Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons | 28 Feb 2025 |
| Genmab A/S has published its Articles of Association | 26 Feb 2025 |
| Capital Increase in Genmab as a Result of Employee Warrant Exercise | 25 Feb 2025 |